The combination of Tafinlar and Mekinist to treat BRAF V600E low-grade glioma has been approved for paediatric patients. Credit: Michal Jarmoluk / Pixabay.

The US Food and Drug Administration (FDA) has granted approval for Novartis’ combination therapy, Tafinlar (dabrafenib) and Mekinist (trametinib), to treat BRAF V600E low-grade glioma (LGG) in paediatric patients as young as one year.

The liquid formulations of Tafinlar and Mekinist also received approval for ease of administration across several approved indications.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This marks the first time a BRAF/MEK inhibitor has been developed in a formulation that is suitable for these patients as young as one year.

These regulatory approvals make Tafinlar + Mekinist the first and only approved combination targeted therapy for BRAF V600E LGG treatment in paediatric patients.

The latest approval represents the sixth for the combination therapy, which is also indicated across several BRAF V600 solid tumours, including lung cancer, melanoma, and thyroid cancer.

Novartis Oncology US executive vice-president Reshema Kemps-Polanco said: “This new indication for Tafinlar + Mekinist is a potential new standard of care treatment option for young patients with this form of brain cancer with a BRAF V600E mutation, in formulations specifically designed for them.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are thankful for the families, including children and adolescents, that participated in the clinical trial that led to this approval and whose bravery has led to a new hope for children living with this serious brain cancer.”

The regulatory approval is based on the data obtained from the Phase II/III TADPOLE trial.

According to the findings, participants treated with Tafinlar + Mekinist had a 47% overall response rate (ORR) compared to those who received chemotherapy.

Dermatitis acneiform, weight increase, fatigue, dry skin, headache, pyrexia, upper respiratory tract infection, diarrhoea, abdominal pain, dizziness, rash, musculoskeletal pain, haemorrhage, nausea, and vomiting were the most common adverse reactions observed.